Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-07-25 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SHANGHAI PUBLIC HEALTH CLINICAL CENTER PRESENTED CLINICAL RESULTS OF ASC22 (ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE FOR FUNCTIONAL CURE OF HIV INFECTION AT THE 12TH IAS CON
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding clinical trial results presented at a scientific conference (the 12th IAS Conference on HIV Science). It provides detailed information about the clinical study, its objectives, and outcomes. There is no indication that this is a full financial report, audit, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. The document is an update on business development related to clinical research, which does not fit into financial or governance categories. Given the nature of the content, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2023-07-25 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a scheduled board meeting to consider and approve the interim results for the six months ended June 30, 2023, and the potential recommendation of an interim dividend. It does not contain any actual financial data or the interim report itself, but rather announces the upcoming board meeting where such results will be reviewed and published. The document length is only 1326 characters, which is quite short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement about the timing of a report or results, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2023-07-21 English
VOLUNTARY ANNOUNCEMENT LETTER OF INTENT FOR COOPERATION IN INVESTMENT PROMOTION PROJECT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by World Houseware (Holdings) Limited regarding a letter of intent for a cooperation investment promotion project related to industrial land and manufacturing expansion. It is not a financial report, earnings release, or regulatory filing of financial results. The document is relatively short (3243 characters) and serves as an announcement of a business development or project intention without financial data or detailed analysis. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or M&A filings. It is also not a regulatory filing or certification. The best fitting category is a general Regulatory Filing (RNS) as it is a voluntary announcement about a business project without specific financial or governance details.
2023-07-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares on various dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong. The content focuses on share repurchase transactions and confirmations related to these transactions. There is no indication of it being a full financial report, earnings release, or management discussion. The document is a regulatory disclosure about share repurchases and capital changes, fitting the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2023-07-20 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT FOR PHASE II CLINICAL TRIAL OF ASC42, AN FXR AGONIST, FOR PRIMARY BILIARY CHOLANGITIS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the completion of patient enrollment for a Phase II clinical trial of a drug candidate ASC42. It provides details about the clinical trial, drug characteristics, and expected topline data release. There is no financial data, no regulatory filing or certification, no voting results, no management or board changes, no earnings or annual report content. The document is an announcement of a business development event, specifically clinical trial progress, not a financial or regulatory report. It is also relatively short (4799 characters) and does not contain detailed financial statements or analysis. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2023-07-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules. The document references specific listing rules from the Stock Exchange of Hong Kong and provides detailed transactional data on share repurchases. This type of document is a regulatory disclosure about transactions in the company's own shares, specifically share buybacks. It is not a full financial report, earnings release, or management discussion. It is not an announcement of a report but a detailed disclosure of share repurchase activity. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail support a high confidence in this classification.
2023-07-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.